Migraine. Migraine without aura
Conditions
Interventions
Intervention 1: First intervention group: Memantine, 5 mg oral tablet (Sobhan company), twice a day for 12 weeks. Then 4 weeks without taking any medication. Then take 200 mg of sodium valproate (Raha
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: A history of migraines based on the criteria of the international community of headache. The number of headache attacks is more than three attacks per month. Failure of prophylactic treatment with one or more migraine prevention drugs. Any headache attack with more than 48 hours of analgesia should be distinguished from other attacks Filling out the consent form of the Clinical trial age 16 to 65
Exclusion criteria
Exclusion criteria: Other headache Use of other migraine prevention medications Drug dependence on drugs or alcohol Renal dysfunction Excessive use of acute migraine attack drugs (more than 8 days in the month of receiving ergots, NSAIDs or tryptans) Sensitization to memantine or sodium valproate or their compounds. Acute resistant migraine Severe psychiatric disorders (bipolar disorder, mental disorder, severe depressive disorder, obsessive-compulsive disorder, or functional disorder, general anxiety disorder, Somatization) Neurodegenerative disorders malignancy , pain disorder, severe infection Pregnant or Breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache score by MIDAS score. Timepoint: At the beginning , 3 month later, 6 month later. Method of measurement: MIDAS score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Abbasi
Ardabil University of Medical Sciences
Outcome results
None listed